Is Deprescription of Ezetimibe Safe in Familial Hypercholesterolemia Patients Taking Evolocumab?

We evaluated whether low-density lipoprotein cholesterol (LDL-C) levels in familial hypercholesterolemia patients on triple lipid-lowering therapy would remain below intensification threshold values after withdrawal of ezetimibe. We included 13 heterozygous familial hypercholesterolemia patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hang, Shyann, Lazarte, Julieta, Hegele, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039577/
https://www.ncbi.nlm.nih.gov/pubmed/35495867
http://dx.doi.org/10.1016/j.cjco.2021.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039577/
https://www.ncbi.nlm.nih.gov/pubmed/35495867
http://dx.doi.org/10.1016/j.cjco.2021.12.005

Ejemplares similares